Tafinlar & Mekinist in combo for Metastatic Melanoma - Details
( Last Updated : September 29, 2015)
Dabrafenib & Trametinib in combo
Tafinlar & Mekinist in combo
Dabrafenib: 50mg and 75mg capsules;Trametinib: 0.5mg and 2.0mg tablets
Skin and Melanoma
Dabrafenib and trametinib in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF 600 mutation.
Pre Noc Submission:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Reimburse with clinical criteria and/or conditions
Final Recommendation Issued:
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.